|Articles|July 5, 2023
New FDA Draft Guidance Shows That the Time for Decentralized Clinical Trials is Now.
Author(s)Science 37
On May 1, 2023, the U.S. Food and Drug Administration (FDA) released an updated Draft Guidance on decentralized trials. This release shows that the landscape of clinical research is rapidly evolving. The shift towards decentralized clinical trials presents an exciting opportunity for sponsors to improve patient engagement, enhance data quality, and accelerate clinical research. Are you prepared for what’s to come? Download the insight brief to learn more.
Trending on Applied Clinical Trials Online
1
Recruitment in the Age of AI: Q&A with John Worden, Javara
2
What It Actually Means to Embed the Patient Voice in Trial Design
3
What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale
4
Why Seizure Counts Alone Can't Define Success in Epilepsy Trials
5